Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
PHAT Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
57.30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
131.90%
PHAT Stock Analysis
PHAT
PE Ratio:
PHAT
PEG Ratio:
Not Available
PHAT
Forward EPS Growth (12 month):
0.00%
PHAT
PS Ratio:
3.9
PHAT
PSG Ratio:
0.1
PHAT
Forward Revenue Growth (12 month):
61.90%
PHAT Articles
No data was found